NCT00073073View on ClinicalTrials.gov

Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Breast Neoplasms
Interventions
DRUG

Exemestane

exemestane 25 mg by mouth (PO) every day for two years

DIETARY_SUPPLEMENT

Calcium carbonate

calcium carbonate 1200 mg PO every day x 2 years

DIETARY_SUPPLEMENT

Vitamin D

Vitamin D 400 international units PO every day x 2 years

Trial Locations (2)

20007

Lombardi Cancer Center, Georgetown University, Washington D.C.

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Georgetown University

OTHER

NCT00073073 - Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer | Biotech Hunter | Biotech Hunter